argenx SE (NASDAQ:ARGX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

argenx SE (NASDAQ:ARGX) has been given a consensus rating of “Moderate Buy” by the twenty-one ratings firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have given a hold recommendation, fourteen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $520.68.

A number of brokerages have recently commented on ARGX. HC Wainwright dropped their target price on argenx from $451.00 to $448.00 and set a “buy” rating for the company in a report on Friday, May 10th. Robert W. Baird dropped their target price on argenx from $505.00 to $490.00 and set an “outperform” rating for the company in a report on Friday, March 1st. Wedbush reiterated an “outperform” rating and issued a $521.00 target price on shares of argenx in a report on Thursday, April 18th. Morgan Stanley decreased their price target on argenx from $515.00 to $510.00 and set an “overweight” rating for the company in a research note on Tuesday, May 28th. Finally, Wolfe Research started coverage on argenx in a research note on Thursday, February 15th. They set a “peer perform” rating for the company.

argenx Price Performance

NASDAQ ARGX opened at $379.30 on Thursday. The stock has a market capitalization of $22.54 billion, a PE ratio of -66.40 and a beta of 0.65. The business has a 50 day simple moving average of $376.30 and a two-hundred day simple moving average of $392.29. argenx has a 1-year low of $327.73 and a 1-year high of $550.76.

argenx (NASDAQ:ARGX) last released its quarterly earnings results on Monday, May 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.33). The firm had revenue of $412.51 million for the quarter, compared to analysts’ expectations of $404.03 million. argenx had a negative net margin of 22.58% and a negative return on equity of 14.14%. During the same quarter in the prior year, the business earned ($0.52) EPS. On average, analysts anticipate that argenx will post -2.75 EPS for the current fiscal year.

Institutional Investors Weigh In On argenx

Several hedge funds have recently made changes to their positions in ARGX. Lindbrook Capital LLC lifted its stake in shares of argenx by 23.1% during the 1st quarter. Lindbrook Capital LLC now owns 197 shares of the company’s stock worth $78,000 after purchasing an additional 37 shares during the last quarter. Wahed Invest LLC increased its holdings in shares of argenx by 9.6% in the fourth quarter. Wahed Invest LLC now owns 457 shares of the company’s stock valued at $174,000 after purchasing an additional 40 shares during the period. Daiwa Securities Group Inc. grew its holdings in argenx by 2.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 1,530 shares of the company’s stock worth $582,000 after acquiring an additional 41 shares during the period. Vanguard Personalized Indexing Management LLC grew its holdings in argenx by 3.1% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 1,428 shares of the company’s stock worth $543,000 after acquiring an additional 43 shares during the period. Finally, Toronto Dominion Bank grew its holdings in argenx by 16.5% during the first quarter. Toronto Dominion Bank now owns 303 shares of the company’s stock worth $119,000 after acquiring an additional 43 shares during the period. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.